View : 37 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author김대기-
dc.date.accessioned2018-05-02T08:15:45Z-
dc.date.available2018-05-02T08:15:45Z-
dc.date.issued2004-
dc.identifier.issn0968-0896-
dc.identifier.otherOAK-2138-
dc.identifier.urihttp://dspace.ewha.ac.kr/handle/2015.oak/242791-
dc.description.abstractA series of 2-pyridinyl-[1,2,4]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 12b showed significant ALK5 inhibition (SBE-Luciferase, 73%; p3TP-Luciferase, 85%) at a concentration of 5μM that is comparable to that of SB-431542 (SBE-Luciferase, 79%; p3TP-Luciferase, 88%), but weak p38α MAP kinase inhibition (4%) at a concentration of 10μM that is much lower than that of SB-431542 (54%). The binding mode of 12b generated by flexible docking studies revealed that the structure of 12b is a good fit into the (NPC-30345)-binding cavity of ALK5. © 2004 Elsevier Ltd. All rights reserved.-
dc.languageEnglish-
dc.titleDesign, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4] triazoles as inhibitors of transforming growth factor β1 type 1 receptor-
dc.typeArticle-
dc.relation.issue9-
dc.relation.volume12-
dc.relation.indexSCI-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.startpage2013-
dc.relation.lastpage2020-
dc.relation.journaltitleBioorganic and Medicinal Chemistry-
dc.identifier.doi10.1016/j.bmc.2004.03.004-
dc.identifier.wosidWOS:000221159800005-
dc.identifier.scopusid2-s2.0-1842636360-
dc.author.googleKim D.-K.-
dc.author.googleKim J.-
dc.author.googlePark H.-J.-
dc.contributor.scopusid김대기(35083694200)-
dc.date.modifydate20180501154232-
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE